Evaluation of clinical outcomes in patients with bloodstream infections due to gram-negative bacteria according to carbapenem MIC stratification

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 9, 2012, Pages 4885-4890

  Esterly, John S ^a,b   Wagner, Jamie ^c   McLaughlin, Milena M ^a,c   Postelnick, Michael J ^a   Qi, Chao ^a   Scheetz, Marc H ^a,c  

^a NORTHWESTERN MEMORIAL HOSPITAL   (United States)

^b CHICAGO STATE UNIVERSITY   (United States)

^c MIDWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAPENEM;

ACINETOBACTER BAUMANNII; ADULT; AGED; ARTICLE; BLOODSTREAM INFECTION; EVALUATION; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; FEMALE; GRAM NEGATIVE BACTERIUM; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RETROSPECTIVE STUDY; SURVIVOR;

ACINETOBACTER BAUMANNII; ADULT; AGED; ANTI-BACTERIAL AGENTS; BACTEREMIA; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; CARBAPENEMS; FEMALE; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; LENGTH OF STAY; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PROBABILITY; PSEUDOMONAS AERUGINOSA; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84865415552     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.06365-11     Document Type: Article

References (36)

1. Ambrose PG, Bhavnani SM, Jones RN, Craig WA, Dudley MN. 2004. Use of pharmacokinetic-pharmacodynamic and Monte Carlo simulation as decision support for the re-evaluation of NCCLS cephem susceptibility breakpoints for Enterobacteriaceae, abstr A-138. Abstr. 44th Intersci. Conf. Antimicrob. Agents Chemother.
2. Arnold RS, et al. 2011. Emergence of Klebsiella pneumoniae carbapenemase- producing bacteria. South. Med. J. 104:40-45.
3. Bhat SV, et al. 2007. Failure of current cefepime breakpoints to predict clinical outcomes of bacteremia caused by gram-negative organisms. Antimicrob. Agents Chemother. 51:4390-4395. (Pubitemid 350209894)
4. Bhavnani SM, Ambrose PG, Craig WA, Dudley MN, Jones RN. 2006. Outcomes evaluation of patients with ESBL-and non-ESBL-producing Escherichia coli and Klebsiella species as defined by CLSI reference methods: report from the SENTRY Antimicrobial Surveillance Program. Diagn. Microbiol. Infect. Dis. 54:231-236.
5. Bhavnani SM, et al. 2010. Pharmacokinetic-pharmacodynamic basis for CLSI carbapenem susceptibility breakpoint changes, abstr A-1382. Abstr. 50th Intersci. Conf. Antimicrob. Agents Chemother.
6. Charlson ME, Pompei P, Ales KL, MacKenzie CR. 1987. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J. Chronic Dis. 40:373-383. (Pubitemid 17055592)
7. Clinical and Laboratory Standards Institute. 2009. Subcommittee on Antimicrobial Susceptibility Testing, January 11-13, summary minutes. http://www.clsi.org/Content/NavigationMenu/Committees/Microbiology/AST/ ArchiveofPreviousEvents/Summary-MinutesASTJan2009.pdf. Accessed on 14 July 2011.
8. Clinical and Laboratory Standards Institute. 2009. Performance standards for antimicrobial susceptibility testing. M100-S119. Clinical and Laboratory Standards Institute, Wayne, PA.
9. Clinical and Laboratory Standards Institute. 2010. Performance standards for antimicrobial susceptibility testing. M100-S120. Clinical and Laboratory Standards Institute, Wayne, PA.
10. Clinical and Laboratory Standards Institute. 2012. Performance standards for antimicrobial susceptibility testing. M100-S122. Clinical and Laboratory Standards Institute, Wayne, PA.
11. Craig WA, Bhavnani SM, Ambrose PG, Dudley MN, Jones RN. 2005. Evaluation of clinical outcomes among patients with ESBL producing Enterobacteriaceae treated with cephalosporin monotherapy, abstr K-1291. Abstr. 45th Intersci. Conf. Antimicrob. Agents Chemother.
12. Craig WA, et al. 2008. Impact of KPCs on the in vivo activity of three carbapenems in the neutropenic mouse-thigh infection model, abstr A-029. Abstr. 48th Intersci. Conf. Antimicrob. Agents Chemother.
13. Defife R, Scheetz MH, Feinglass JM, Postelnick MJ, Scarsi KK. 2009. Effect of differences in MIC values on clinical outcomes in patients with bloodstream infections caused by gram-negative organisms treated with levofloxacin. Antimicrob. Agents Chemother. 53:1074-1079.
14. Deyo RA, Cherkin DC, Ciol MA. 1992. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J. Clin. Epidemiol. 45:613-619.
15. Dudley MN, et al. 25 January 2010, posting date. CLSI Working Group. http://www.clsi.org/Content/NavigationMenu/Committees/Microbiology/AST/ January2010ASTMeetingPresentations/ EnterobacteriaceaeWGCarbapenemBreakpointDiscussionSlides.pdf Accessed on 28 June 2011.
16. Esterly JS, Qi C, Malczynski M, Scheetz MH. 2010. Predictability of doripenem susceptibility in Acinetobacter baumannii isolates based on other carbapenem susceptibilities and bla OXA gene status. Pharmacotherapy 30:354-360.
17. Hosmer DW, Lemeshow S. 2000. Applied logistic regression, 2nd ed, p 31-46. Wiley & Sons, Hoboken, NJ.
18. Hosmer DW, Lemeshow S. 2000. Applied logistic regression, 2nd ed, p 91-142. Wiley & Sons, Hoboken, NJ.
19. Infectious Diseases Society of America. 2011. Standards, practice guidelines, and statements developed and/or endorsed by IDSA. http://www.idsociety.org/Content.aspx?id=9088. Accessed 5 July 2011.
20. Jones RN, Sader HS, Fritsche TR, Rhomberg PR. 2006. Carbapenem susceptibility discords among Acinetobacter isolates. Clin. Infect. Dis. 42:158. (Pubitemid 41832100)
21. Kang CI, et al. 2005. Bloodstream infections caused by antibioticresistant gram-negative bacilli: risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome. Antimicrob. Agents Chemother. 49:760-766.
22. Kollef KE, et al. 2008. Predictors of 30-day mortality and hospital costs in patients with ventilator-associated pneumonia attributed to potentially antibiotic-resistant gram-negative bacteria. Chest 134:281-287.
23. Krueger WA, et al. 2005. Evaluation by Monte Carlo simulation of the pharmacokinetics of two doses of meropenem administered intermittently or as a continuous infusion in healthy volunteers. Antimicrob. Agents Chemother. 49:1881-1889. (Pubitemid 40631603)
24. Lee LS, et al. 2010. Comparison of 30-min and 3-h infusion regimens for imipenem/cilastatin and for meropenem evaluated by Monte Carlo simulation. Diagn. Microbiol. Infect. Dis. 68:251-258.
25. Lesho E, Wortmann G, Moran K, Craft D. 2005. Fatal Acinetobacter baumannii infection with discordant carbapenem susceptibility. Clin. Infect. Dis. 41:758-759. (Pubitemid 41170368)
26. Lodise TP, Jr, et al. 2007. Predictors of 30-day mortality among patients with Pseudomonas aeruginosa bloodstream infections: impact of delayed appropriate antibiotic selection. Antimicrob. Agents Chemother. 51:3510-3515.
27. Merck. 2010. Primaxin IV package insert. Merck & Co., Whitehouse Station, NJ.
28. Micek ST, et al. 2005. Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment. Antimicrob. Agents Chemother. 49:1306-1311. (Pubitemid 40463352)
29. Michalopoulos A, Falagas ME. 2010. Treatment of Acinetobacter infections. Expert Opin. Pharmacother. 11:779-788.
30. Patel JB. 27 September 2007, posting date. Carbapenem resistance in Enterobacteriaceae. Centers for Disease Control and Prevention, Atlanta, GA. http://www.state.nj.us/health/phel/documents/teleconf/carbapenem-powerpoint.ppt. Accessed on 14 July 2011.
31. Rhomberg PR, Jones RN. 2009. Summary trends for the Meropenem Yearly Susceptibility Test Information Collection Program: a 10-year experience in the United States (1999-2008). Diagn. Microbiol. Infect. Dis. 65:414-426.
32. Rodriguez-Martinez JM, Poirel L, Nordmann P. 2009. Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 53:4783-4788.
33. Sakka SG, et al. 2007. Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenem-cilastatin in critically ill patients in a randomized, controlled trial. Antimicrob. Agents Chemother. 51:3304-3310. (Pubitemid 350067544)
34. Scheetz MH, Esterly JS, Malczynski M, Postelnick M, Qi C. 2009. Impact of dissimilar susceptibility breakpoints for doripenem on susceptibility and carbapenem discordance for Pseudomonas aeruginosa. Diagn. Microbiol. Infect. Dis. 64:465-467.
35. Tam VH, et al. 2008. Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint. Clin. Infect. Dis. 46:862-867. (Pubitemid 351417187)
36. Weisenberg SA, Morgan DJ, Espinal-Witter R, Larone DH. 2009. Clinical outcomes of patients with Klebsiella pneumoniae carbapenemaseproducing K. pneumoniae after treatment with imipenem or meropenem. Diagn. Microbiol. Infect. Dis. 64:233-235.